Review Article
The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
Table 1
Comparing main studies in terms of median survival, 5-year survival rates, and morbidity.
| Authors | Year published | Type of study | Stage of GC | Number of patients | Type of protocol | Median survival (months) | 5-year survival rates | Morbidity |
| Fujimoto et al. [21] | 1999 | RCT | Stage II-III | 141 | HIPEC + surgery versus surgery alone | N/A | 76% versus 57% | N/A |
Kim and Bae [7] | 2001 | PCS | Stage III-IV | 103 | HIPEC + CRS versus surgery alone | 36 versus 22.9 | 32.7% versus 27.1% | 33.2% versus 36.5% | Yonemura et al. [8] | 2001 | RCT | Stage II-III | 139 | HIPEC + surgery versus NIC + surgery versus surgery alone | N/A | 61% versus 43% versus 42% | 4% versus 0% versus 4% | Yonemura et al. [9] | 2009 | PCS | Stage III-IV | 79 | NIPS versus NIPS + surgery | N/A | 20.4% versus 40%* | 11.4% | Glehen et al. [10] | 2010 | RCS | Stage III-IV | 159 | HIPEC + EPIC versus EPIC HIPEC | 9.2 (overall) | 13% (overall) | 27.8% (overall) |
|
|
HIPEC: hyperthermic intraperitoneal chemotherapy; EPIC: early postoperative intraperitoneal chemotherapy; PIC: perioperative intraperitoneal chemotherapy; NIC: normothermic intraperitoneal chemotherapy; NIPS: neoadjuvant intraperitoneal and systemic chemotherapy; NIIC: normothermic Intraoperative Intraperitoneal Chemotherapy; DPIC: Delayed Postoperative Intraperitoneal Chemotherapy; RCS: Retrospective Case Series; PCS: Prospective cohort study; PCS: prospective case series; N/A: not available.
*2-year survival rates.
|